CIPLA
Back to Income Statement
|
CIPLA Last 5 Year Consolidated Net Profit History
[Consolidated]
| Mar2026 | Mar2025 | Mar2024 | Mar2023 | Mar2022 | |
|---|---|---|---|---|---|
| Consolidated Net Profit | ₹5,273 Cr | ₹4,122 Cr | ₹2,802 Cr | ₹2,517 Cr | ₹2,405 Cr |
What is the latest Consolidated Net Profit of CIPLA ?
| Year | Consolidated Net Profit |
|---|---|
| Mar2026 | ₹5,273 Cr |
| Mar2025 | ₹4,122 Cr |
| Mar2024 | ₹2,802 Cr |
| Mar2023 | ₹2,517 Cr |
| Mar2022 | ₹2,405 Cr |
How is Consolidated Net Profit of CIPLA Trending?
| Years | Consolidated Net Profit | % Change | |
|---|---|---|---|
| Mar2026 | ₹5,273 Cr | 27.93 | |
| Mar2025 | ₹4,122 Cr | 47.10 | |
| Mar2024 | ₹2,802 Cr | 11.33 | |
| Mar2023 | ₹2,517 Cr | 4.65 | |
| Mar2022 | ₹2,405 Cr | - | |
Compare Consolidated Net Profit of peers of CIPLA
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| CIPLA | ₹117,413.7 Cr | 2.7% | 2.5% | -4% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹449,299.0 Cr | 0.5% | 1.5% | 11.9% | Stock Analytics | |
| DIVIS LABORATORIES | ₹174,207.0 Cr | -3.3% | -3.5% | 1.8% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹157,721.0 Cr | 4.5% | 2.6% | 42.6% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹114,876.0 Cr | 6.6% | 4.3% | 1.9% | Stock Analytics | |
| MANKIND PHARMA | ₹102,642.0 Cr | -2% | 2.7% | 7.5% | Stock Analytics | |
CIPLA Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| CIPLA | 2.7% |
2.5% |
-4% |
| SENSEX | -0.1% |
1% |
-5.7% |
You may also like the below Video Courses